NCT06192849View on ClinicalTrials.gov

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

January 31, 2027

Conditions

Non Small Cell Lung CancerEGFR Exon 20 Insertion Mutation

Interventions

DRUG

Furmonertinib

This arm plans to enroll 20 subjects, treating with furmonertinib 160mg/d, until disease recurrence, death or intolerability. The maximum duration of treatment is three years.

Trial Locations (1)

610000

RECRUITING

Sichuan cancer hospital, Chengdu

All Listed Sponsors

lead

Juan LI, MD

OTHER